Trials / Completed
CompletedNCT00519987
Multiple Dose Pharmacokinetics of Intranasal Ketamine
An Open Label, Single Center Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Administrations of 30 mg PMI-150 (Intranasal Ketamine) in Healthy Adult Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 18 (actual)
- Sponsor
- Javelin Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.
Detailed description
To examine safety and characterize the repeat dosing plasma profile, effect on absorption, and accumulation following repeated administration of 30 mg doses of PMI-150 (intranasal ketamine) to healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | intranasal ketamine | intranasal ketamine |
Timeline
- Start date
- 2007-06-01
- Primary completion
- 2007-08-01
- Completion
- 2007-08-01
- First posted
- 2007-08-23
- Last updated
- 2008-01-10
Source: ClinicalTrials.gov record NCT00519987. Inclusion in this directory is not an endorsement.